Expression levels of tumor biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are pivotal for treatment decisions and prognostication in breast cancer. This evidence concerns the gene PGR and breast carcinoma.